West Pharmaceutical Services (NYSE:WST) Hits New 52-Week High - Should You Buy?

Key Points

• Shares hit a new 52‑week high at $323.29 and the stock carries a consensus rating of "Moderate Buy" with an average price target of about $322.89 after multiple firms reiterated buy/outperform views.
• Quarterly earnings beat: West reported $2.13 EPS vs. $1.68 expected and revenue of $844.9M (up 21% YoY); the company guided FY2026 EPS to $8.40–8.75 while analysts model roughly $8.61 for the year.
• Capital returns and strong balance sheet: the board approved a $1.0 billion share buyback (up to ~5.6% of shares), the firm pays a modest $0.22 quarterly dividend (≈0.3% yield), and carries a low debt-to-equity ratio of 0.07.

West Pharmaceutical Services, Inc. (NYSE:WST - Get Free Report) shares hit a new 52-week high on Thursday . The stock traded as high as $323.29 and last traded at $323.4840, with a volume of 710743 shares. The stock had previously closed at $312.55.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on WST shares. UBS Group reiterated a "buy" rating and set a $340.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Citigroup reiterated a "buy" rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Evercore reiterated an "outperform" rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $295.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, West Pharmaceutical Services has an average rating of "Moderate Buy" and a consensus price target of $322.89.

West Pharmaceutical Services Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The stock has a market cap of $22.78 billion, a price-to-earnings ratio of 43.11, a P/E/G ratio of 2.59 and a beta of 1.17. The stock's 50-day moving average is $259.93 and its 200 day moving average is $263.91.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm's revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 8.61 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 11.76%.

West Pharmaceutical Services announced that its Board of Directors has approved a share buyback plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Insider Transactions at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company's stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On West Pharmaceutical Services

Hedge funds and other institutional investors have recently modified their holdings of the stock. Elyxium Wealth LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at approximately $25,000. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $25,000. Cornerstone Planning Group LLC lifted its position in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 50 shares during the period. Bayban acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at approximately $27,000. Finally, Private Trust Co. NA lifted its position in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.